We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks
Agilent Technologies (A)
An SI Board Since August 1999
Posts SubjectMarks Bans Symbol
620 79 0 A
Emcee:  Kirk © Type:  Moderated

Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling customers to gain the insights they seek. Agilent’s expertise and trusted collaboration give them the highest confidence in our solutions.

Agilent focuses its expertise on six key markets:

Food: Agilent helps ensure that our global food supply is free of contaminants—whether chemical, viral, bacterial or microbiological. Our customers include government regulators and labs that control food safety, as well as private companies that produce, package and sell food to the public.

Environmental and Forensics: From pesticides to pharmaceutical residues to trace metals, we provide fast, accurate and sensitive methods for monitoring contaminants affecting quality of life. Agilent solutions also play an important role in law enforcement by providing robust tools and instruments to analyze and verify evidence at trial, and keeping the world’s top-performing athletes honest.

Pharmaceutical: Agilent has one of the broadest solutions portfolios of any company serving the pharmaceutical industry. Our solutions provide precise answers for every segment of the pharmaceutical industry, from disease research and drug discovery to drug development, manufacturing and quality control. The start-to-finish solution set means customers can get products to market faster. Customers trust us to help them test the purity of their therapeutics. Agilent also ensures that their instruments and processes conform to the highest compliance regulations.

Diagnostics: Agilent gives doctors a head start in the fight against cancer and other diseases. Our solutions help pathology laboratories deliver fast, accurate information to the doctors, hospitals and medical centers they serve. We help medical professionals make more accurate diagnoses so patients can receive the most effective therapies.

Chemical and Energy: The world runs on energy, and energy companies need to locate, extract and refine fuels efficiently and cost-effectively. Our solutions help customers maximize their production and predict failures in their refineries before they happen. Agilent also helps energy researchers investigate biofuels, renewable fuels and other forms of alternate energy.

Research: Most life sciences and diagnostics research is done at top-tier universities, with funding from governments around the world. Agilent is helping these researchers learn more about cancer, cardiovascular diseases, diabetes, Alzheimer’s, Parkinson’s, autism and other ailments. Our instruments, software and sample preparation solutions help scientists conduct faster, more accurate research.

Read about the Agilent products and solutions that serve these markets.

Disclosure: At the time of this update (8/18/15) I own Agilent stock and cover it in my newsletter where I currently have a listed price to sell shares should they surge in value.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
620Good report. Up $6.82 or 4.7% in AH trading. Agilent Reports Fourth-Quarter anKirk ©1November 21
619Yup, been a GREAT stock to own and trade around a core position for added returnKirk ©-2/17/2021
618First post since 3/2017. ATH $131.08 Close $127.95 2/16Sr K-2/16/2021
617You gotta love how one of the better "weather vanes" suddenly discoverKirk ©13/24/2017
616n an uncertain health care market, one biotechnology player stands out to Jim CrJakeStraw-3/24/2017
615A makes a small acquisition. on 4:05 pm Agilent will acquire MulSr K112/20/2016
614Note using cash to invest in growth rather than buybacks lowers EPS 2 to 3 centsKirk ©-3/9/2016
613Hi more 100, Noticed it opened down, but is now up. Nothing severe. Bobrobert b furman-2/17/2016
612Agilent ($A) reported better than expected first quarter non-GAAP earnings per smore100-2/17/2016
611A break of $40.12 could move it up to $46.86. %K and %D go green and RSI increassfnsie18/19/2015
610Thanks Bob Good news from the Conf Call As a reminder, I highlighted three focuKirk ©-8/18/2015
609Kirk would be great moderator here! Bobrobert b furman28/18/2015
608OK, I'll do it.Kirk ©48/18/2015
607Need a new moderator for this board, a show of hands please for anyone who wantsSI Ron (Crazy Soup Man)-8/18/2015
606The market likes this report from my biotech picks and shovels stock finance.yaKirk ©-8/18/2015
605Agilent Technologies Inc. (NYSE: A) was reiterated as Buy with a fair value estKirk ©-8/18/2015
604One of those robot generated news stories.... Agilent misses Street 2Q forecastKirk ©-5/18/2015
603Agilent spins off Keysight Friday. Keysight Technologies and Halyard Health SetKirk ©110/29/2014
6027:30AM Agilent to separate into two public companies; spinoff is not anticipatedSr K-9/19/2013
601Agilent Technologies Reports Third-Quarter 2013 ResultsHighlights: Highlights: Kirk ©-8/15/2013
600A has really done a great job leaving cyclical semi and going inot medical. Nicrobert b furman15/17/2012
599Agilent to Acquire Dako for $2.2 Billion Thu May 17,Kirk ©-5/17/2012
598Yeah, great results. All business groups grew... not a lot but ANY growth theseKirk ©-5/14/2012
597Up a buck in AH !!robert b furman15/14/2012
596NIce, Improvement in all aspects. Now we need to hear that from AMAT next weekrobert b furman-5/14/2012
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):